
    
      This study will be conducted in a randomized, open-label, multi-center design. On Day 1 of
      chemotherapy, approximately 90 subjects screened and determined eligible will be randomized
      to either Group A or Group B in a 1:1 manner for study participation.

        -  Group A: Upon the EOC, subjects will receive tenofovir 300mg for approximately 6 months
           (24 weeks) and undergo treatment and follow-up every 12 weeks for up to 72 weeks post
           chemotherapy.

        -  Group A: Upon the EOC, subjects will receive tenofovir 300mg for approximately 12 months
           (48 weeks) and undergo treatment and follow-up every 12 weeks for up to 72 weeks post
           chemotherapy.
    
  